Neoadjuvant KEYTRUDA® (pembrolizumab) + chemotherapy followed by adjuvant KEYTRUDA monotherapy in patients with triple-negative breast cancer (TNBC)
Prescribing Information [External link]
KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer, at high-risk of recurrence.1
For more information about KEYTRUDA in TNBC explore our product page
Managing immune-mediated Adverse Events
Prescribing Information [External link]
Please refer to Summary of Product Characteristics for full list of AEs and management.
KEYTRUDA® (pembrolizumab) + chemotherapy for patients with locally recurrent unresectable or metastatic TNBC
Prescribing Information [External link]
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.1
For more information about KEYTRUDA in TNBC explore our product page
Please refer to the SmPC for further information before making any prescribing decisions.
References
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
